Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration.
about
Lentiviral gene transfer of RPE65 rescues survival and function of cones in a mouse model of Leber congenital amaurosisMacular translocation for neovascular age-related macular degenerationSubmacular surgery for choroidal neovascularisation secondary to age-related macular degenerationRetinal toxicity of commercial tissue plasminogen activator is mediated by the induction of nitric oxide in the mouse retinal primary cells.Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration.Tissue plasminogen activator-assisted vitrectomy for submacular hemorrhage due to age-related macular degenerationDisplacement of submacular hemorrhage associated with age-related macular degeneration using vitrectomy and submacular tPA injection followed by intravitreal ranibizumabGuidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).Six-month visual prognosis in eyes with submacular hemorrhage secondary to age-related macular degeneration or polypoidal choroidal vasculopathy.Recombinant tissue plasminogen activator, vitrectomy, and gas for recent submacular hemorrhage displacement due to retinal macroaneurysm.Vitrectomy for the treatment of submacular hemorrhages from macular degeneration: a comparison of submacular hemorrhage/membrane removal and submacular tissue plasminogen activator-assisted pneumatic displacement.Clinical characteristics and current treatment of age-related macular degeneration.Retinal toxicity of intravitreal tenecteplase in the rabbitSuccessful displacement of a traumatic submacular hemorrhage in a 13-year-old boy treated by vitrectomy, subretinal injection of tissue plasminogen activator and intravitreal air tamponade: a case reportManagement of subretinal macular haemorrhage by direct administration of tissue plasminogen activator.Pars plana vitrectomy with peripheral retinotomy after injection of preoperative intravitreal tissue plasminogen activator: a modified procedure to drain massive subretinal haemorrhageThe retinal tolerance to bevacizumab in co-application with a recombinant tissue plasminogen activator.Submacular predominantly hemorrhagic choroidal neovascularization: resolution of bleedings under anti-VEGF therapy.Submacular hemorrhage: a study amongst Indian eyes.Polypoidal choroidal vasculopathy in Korean patients with large submacular hemorrhage.Vitrectomy with subretinal tissue plasminogen activator and ranibizumab for submacular haemorrhages secondary to age-related macular degeneration: retrospective case series of 45 consecutive casesIntravitreal anti-VEGF monotherapy for thick submacular hemorrhage of less than 1 week duration secondary to neovascular age-related macular degenerationRetinal safety of intravitreal rtPA in healthy rats and under excitotoxic conditions.Surgical treatment of age-related macular degeneration.Treatment for submacular hemorrhage associated with neovascular age-related macular degeneration.Literature review of recombinant tissue plasminogen activator used for recent-onset submacular hemorrhage displacement in age-related macular degeneration.Radiating hemorrhage in exudative age-related macular degeneration.A New Method of Subretinal Injection of Tissue Plasminogen Activator and Air in Patients With Submacular Hemorrhage.Effect of amiloride to retinal toxicity induced by tissue plasminogen activator.Surgically Induced Focal Retinal Detachment Does Not Cause Detectable SD-OCT Retinal Changes in Normal Human RetinaSubretinal recombinant tissue plasminogen activator and pneumatic displacement for the management of subretinal hemorrhage occurring after anti-VEGF injections for wet AMD.Intravitreal recombinant tissue plasminogen activator without and with additional gas injection in patients with submacular haemorrhage associated with age-related macular degeneration.Retinal sensitivity after displacement of submacular hemorrhage due to polypoidal choroidal vasculopathy: effectiveness and safety of subretinal tissue plasminogen activator.Vitrectomy in patients 85 years of age and older: surgical outcomes and visual prognosis.Volumetric Measurement of Subretinal Blebs Using Microscope-Integrated Optical Coherence Tomography.Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage.Polypoidal Choroidal Vasculopathy.Development of Submacular Hemorrhage in Neovascular Age-related Macular Degeneration: Influence on Visual Prognosis in a Clinical Setting
P2860
Q21144697-CDF0302A-F894-47AD-AB79-ADE9EDA858AEQ24241142-D3EFBCAC-B2BB-4B0B-9F5F-2952CAFFDE17Q24241790-4C0CEF83-E382-468F-BDFD-A94A56280D3BQ33219549-7448607D-21C4-40C7-9988-F690CCF9ECF2Q33682143-3952413B-09A5-4C55-BAD0-AE2A4803C83AQ33900503-24D1A755-FC37-4DC3-90CF-C50ACA7561A4Q34019693-C03AE5C5-EE57-4C46-B2B6-4726B7760B0CQ34092454-52169636-D157-4DF9-A9AD-6F2866E4893DQ34283774-D7727A30-B851-4B38-A281-47118CF942B7Q34366841-1777507D-B9C1-4A4C-A872-4D812C6472CBQ34565343-AAC6A330-5F67-4A12-83E7-A94A07513591Q34930298-C889FBC5-F7DA-4E02-AE3D-4EFDB02F513AQ35591883-50758797-C4B6-4979-B839-D65EE7626A81Q35739329-7387CEB5-8469-402A-888B-395B5DB395A3Q35761653-A0BA74F2-4A31-4E28-A6B1-504011D4276CQ35762940-43E54179-E9B6-4FE2-A7B4-A0DF07249F3CQ35953759-D5091A83-7813-4A2D-8679-48CB3B165A78Q36010407-F9869BBB-22D0-4325-B5E3-15DFE8798DAAQ36533061-A816CEC0-0C84-4ED4-83F0-1FFE03D7C978Q37065541-D0E8D0D0-9F96-4B31-83A2-E52C46A8EEB0Q37085388-91FBB0CC-53EB-42A4-AFD7-F2B9A1CCF3E8Q37318998-A216CB4C-D702-41D1-8344-9A2B104954EBQ37412847-FA936590-18A3-4811-9AD2-97A77FF3D141Q37879175-2DF0860A-1C9E-44F5-BA79-0F69B6979E1CQ37951624-9BF4A008-9DCF-40A1-B8C6-E511A0400370Q38052994-1C08CB79-DCE0-4928-89D4-F2AC2DB44E13Q40525714-FBBDAF3B-B4E2-4795-A75E-A01E4167A8DEQ41322369-D63985A7-7449-4495-9722-0C09A59E6B16Q41982309-2F54E7BF-4CC1-4DD3-A71B-4B6C69B9C421Q42379453-BD3AB6D5-2BA6-42B6-8C63-A02E779D4214Q42729433-144FCA48-2C31-4B79-A2B7-628FDA501B72Q44642952-7FF39721-B643-4C47-8A7C-CA64C84B4335Q47913027-AEEC0B86-759A-42EA-A7E1-AE7F9165143BQ50314620-88BBF4E0-76C5-4C8B-9269-F5FC1F692E13Q53693262-638EDD5A-7919-4139-BD64-730447404EACQ54286581-B77166A5-F45B-44DF-8855-A7ED90D421E0Q55714679-38598911-B031-4188-9B9F-9C4B8D30E3F1Q57488312-38208F75-848F-4068-93BF-68576DECA826
P2860
Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pars plana vitrectomy, subreti ...... -related macular degeneration.
@ast
Pars plana vitrectomy, subreti ...... -related macular degeneration.
@en
type
label
Pars plana vitrectomy, subreti ...... -related macular degeneration.
@ast
Pars plana vitrectomy, subreti ...... -related macular degeneration.
@en
prefLabel
Pars plana vitrectomy, subreti ...... -related macular degeneration.
@ast
Pars plana vitrectomy, subreti ...... -related macular degeneration.
@en
P2093
P1476
Pars plana vitrectomy, subreti ...... -related macular degeneration.
@en
P2093
Haupert CL
McCuen BW 2nd
P304
P356
10.1016/S0002-9394(00)00734-0
P407
P577
2001-02-01T00:00:00Z